Skip to Content
Merck
  • CRB3 downregulation confers breast cancer stem cell traits through TAZ/β-catenin.

CRB3 downregulation confers breast cancer stem cell traits through TAZ/β-catenin.

Oncogenesis (2017-04-25)
P Li, Y Wang, X Mao, Y Jiang, J Liu, J Li, J Wang, R Wang, J She, J Zhang, J Yang, Y Liu, P Liu
ABSTRACT

The cancer stem cell (CSC) theory depicts a special population within the cancer mass that self-renew and sustain the cancer, even if the other cells were eliminated by therapies. How CSCs acquire these unique traits is still unclear. Crumbs homolog 3 (CRB3), a member of the CRB polarity complex, has been reported to act as a tumor suppressor. Here, we detected significantly lower or negative CRB3 expression in human breast cancer tissues. Knockdown of CRB3 generated non-tumorigenic, immortalized breast epithelial cell line MCF 10A with CSC properties. Simultaneously, we found that CRB3 downregulation induced the epithelial-mesenchymal transition and activated TAZ (transcriptional co-activator with PDZ-binding motif) and β-catenin. Significantly, the activation of TAZ and β-catenin sufficed in conferring MCF 10A cells with CSC properties. This study demonstrates that cell polarity proteins may serve as a switch of the differentiated vs multipotent states in breast cancers.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-CRB3 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Sigma-Aldrich
Monoclonal Anti-Actin, α-Smooth Muscle, clone 1A4, ascites fluid